Clinical trials: B-cell
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT01987349
- Testing
- Fluzone® (intramuscular), FluMist® (intranasal)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Stanford University
Diphtheria, Tetanus
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China
The study will assess the safety of Pentaxim® vaccine as a three-dose primary vaccination at 2, 3, and 4 months of age in order to meet the regulatory requirements for the license renewal as for any other product registered in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT01491087
- Testing
- DTacP IPV//PRP~T combined vaccine: PENTAXIM®
- Where
- 3 sites in China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Primary Sjögren's Syndrome, Xerostomia
Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome
The primary purpose of the study is to determine whether B-cell depletion with Rituximab has an effect on the oral, ocular and general disease manifestations in patients with primary Sjögren´s syndrome, that is, an effect on the…
- Conditions
- Primary Sjögren's Syndrome, Xerostomia, Hyposalivation, Keratoconjunctivitis Sicca
- Trial name
- NCT00426543
- Testing
- MabThera (rituximab), Rituximab, Mabthera
- Where
- Denmark
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
HIV Infections
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
The purpose of this study is to evaluate the immune response to the Vaccine Research Center (VRC) rAd5 HIV vaccine when the vaccine components are administered in three different ways, in healthy, HIV-uninfected adults.
- Trial name
- NCT01479296
- Testing
- VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C), rAd5 env A, rAd5 env B
- Where
- 8 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Immunisation
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
This was a Phase IV open label and single arm study, with the aim of enrolling up to 55 healthy males and non-pregnant females in a single site, age 18-49 years old, inclusive.
- Trial name
- NCT02485639
- Testing
- Influenza Virus Vaccine Inactivated
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
RATIONALE: Drugs used in chemotherapy, such as fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00845104
- Testing
- fludarabine phosphate, rituximab, bevacizumab
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Hepatitis B Vaccination, Immune Response
Study of the Cellular Response Induced After Vaccination Against the Hepatitis B Virus
296 million people worldwide are infected with the hepatitis B virus (HBV), despite the existence of an effective prophylactic vaccine.
- Conditions
- Hepatitis B Vaccination, Immune Response, T Cells
- Trial name
- HBVax (NCT06876467)
- Testing
- Evaluation of cellular response
- Where
- France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leukemia
Genetic Study of Chronic Lymphocytic Leukemia Families
The goal of this research is to identify genes that may be related to the risk of developing CLL. Objectives: The objective of this study to investigate possible candidate susceptibility genes for familial chronic lymphocytic…
- Trial name
- NCT00503256
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Hepatitis B Vaccination
Immune Response to Hepatitis B Virus Booster Vaccination After 20-23 Years
This study will evaluate the humoral and cellular immune responses to a hepatitis B vaccine booster in healthy adults which received a full course of neonatal hepatitis B vaccination 20-23 years ago.
- Trial name
- NCT02166671
- Testing
- HBV booster vaccination 1dose
- Where
- South Korea
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Influenza
Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization
The purpose is to investigate B-cell response to the trivalent Influenza Vaccine (TIV) in healthy young adults by vaccinating participants and obtaining blood samples at designated time points before and after vaccination.
- Trial name
- SLVP023 (NCT02987374)
- Testing
- 2011-2012 Fluzone IIV3 (IM)
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Leukemia, Lymphocytic, Chronic, B-Cell
Combination of Ibrutinib and As2O3 in the Treatment of CLL
The purpose of this study is to determine whether the combination of As2O3 and ibrutinib is synergistic in chronic lymphocytic leukemia
- Trial name
- NCT02757040
- Testing
- Ibrutinib combined with As2O3, ibrutinib
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Diffuse Large B-cell Lymphoma(DLBCL)
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
Zanubrutinib is a highly specific, potent new Bruton's tyrosine kinase （BTK） inhibitor, with minimal off-target inhibition of other kinases.
- Trial name
- NCT05189197
- Testing
- Zanubrutinib + R-CHOP
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Fudan University
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
Diffuse large B-cell lymphomas (DLBCL) are highly aggressive and heterogeneous B-cell lymphoma that would imminently be fatal without treatment.
- Trial name
- ExoReBLy (NCT03985696)
- Testing
- blood sample
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Multiple Myeloma
Serum Soluble BCMA as a Non-Invasive Marker in Multiple Myeloma
This prospective study aims to investigate serum soluble B-cell maturation antigen (sBCMA) as a non-invasive marker in patients with multiple myeloma and to compare its levels with healthy controls.
- Trial name
- NCT07855718
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Multiple Sclerosis, Systemic Sclerosis
Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients
New therapeutic approaches of MS are emerging, targeting different actors of the immune system. Some of them target a specific population of white blood cells: B lymphocytes composed of different subpopulations.
- Trial name
- B-MS (NCT02789670)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
HIV Infections
Immunologic Memory (Supp. of ATN 024)
This is an exploratory, laboratory-based evaluation of cellular immune response to immunization with hepatitis B surface antigen in HIV-infected and HIV-uninfected adolescents. This is a substudy of ATN 024 and ATN 025.
- Trial name
- NCT00142753
- Testing
- Engerix B, Twinrix for ATN 024, Recombivax
- Where
- 4 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Malaria, Diabetes Mellitus
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Non-communicable diseases (NCDs) such as diabetes are increasing in countries where malaria transmission is common. This study aims to investigate the relationship between NCDs and parasitic infections in Cameroon.
- Conditions
- Malaria, Diabetes Mellitus, Metabolic Syndrome, Endemic
- Trial name
- NCT06278181
- Where
- Cameroon
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Chronic Hepatitis B Virus
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient.
- Trial name
- LiNKeB2 (NCT06853886)
- Testing
- blood sample HBV patient, blood sample healthy volunteers
- Where
- 3 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Type I Diabetes
Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan
This study will test dihydrotetrabenazine, or 11C-DTBZ, a radioactive tracer, as an imaging agent in positron emission tomography (PET).
- Trial name
- NCT00351650
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)